Anti-Rheumatic Drugs - Kuwait

Kuwait

The Anti-Rheumatic Drugs market in Kuwait is anticipated to witness a substantial increase in revenue, with projections indicating a rise to US$22.43m in 2024.
This growth is expected to continue at an annual growth rate of 0.89% from 2024 to 2029, resulting in a market volume of US$23.45m by 2029.
It is worth noting that in a global context, United States is projected to generate the highest revenue of US$34,700.00m in 2024.
"The demand for anti-rheumatic drugs in Kuwait is steadily increasing due to the rising prevalence of rheumatic diseases in the country."

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Kuwait has been on the rise in recent years.

Customer preferences: Patients in Kuwait with rheumatic diseases prefer Anti-Rheumatic Drugs that are effective in reducing inflammation and pain. They also prefer drugs that have minimal side effects and are convenient to use. Due to the high cost of these drugs, patients in Kuwait prefer to purchase them through their health insurance or government subsidies.

Trends in the market: The Anti-Rheumatic Drugs market in Kuwait has been growing steadily due to an increase in the prevalence of rheumatic diseases in the country. This has led to an increase in demand for Anti-Rheumatic Drugs. The market is also being driven by the introduction of new and innovative drugs that are more effective in treating rheumatic diseases. The market is expected to continue growing as the population ages, and the prevalence of rheumatic diseases continues to rise.

Local special circumstances: Kuwait has a high prevalence of rheumatic diseases, which is attributed to the hot and dry climate in the country. The dry climate can cause joint pain and inflammation, leading to the development of rheumatic diseases. The high prevalence of rheumatic diseases in Kuwait has led to an increase in demand for Anti-Rheumatic Drugs.

Underlying macroeconomic factors: The Kuwaiti government has been investing heavily in healthcare in recent years, which has led to an increase in the availability of healthcare services in the country. This has led to an increase in demand for Anti-Rheumatic Drugs as more patients are able to access healthcare services. The high cost of these drugs has led the government to subsidize them, making them more affordable for patients. The government’s investment in healthcare is expected to continue, which will further boost the demand for Anti-Rheumatic Drugs in Kuwait.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.